

HEALTHWAY MEDICAL CORPORATION LIMITED

(Registration No.: 200708625C)
(Incorporated in the Republic of Singapore)

EMPHASIS OF MATTER BY INDEPENDENT AUDITOR ON THE AUDITED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2017

Pursuant to Rule 704(4) of the Listing Manual of the Singapore Exchange Securities Trading Limited (“**SGX-ST**”) Section B: Rules of Catalist (“**Catalist Rules**”), the Board of Directors (“**Board**”) of Healthway Medical Corporation Limited (the “**Company**”) wishes to announce that its Independent Auditor, PricewaterhouseCoopers LLP, has issued its Independent Auditors’ Report dated 28 March 2018 to the financial statements of the Company and its subsidiaries (the “**Group**”) for the financial year ended 31 December 2017 (“**Independent Auditors’ Report**”) and included an Emphasis of Matter as the independent reviewer appointed to look into the extension of loans by the Group to Healthway Medical Enterprises Pte. Ltd. and Wei Yi Shi Ye Co. Ltd., with the objective of establishing whether there are any breaches of the SGX-ST Listing Manual Section B: Rules of Catalist has yet to finalise their report. The audit opinion of the Independent Auditors’ Report, however, is not modified in respect of this matter.

Please refer to a copy of the Independent Auditors’ Report, together with the extract of Note 31 of the financial statements, annexed to this announcement for further information.

The Independent Auditors’ Report and a complete set of the Group’s audited financial statements for the financial year ended 31 December 2017 (“**FY2017**”) will form part of the Company’s annual report for FY2017 (“**FY2017 Annual Report**”) which will be released on SGXNET and sent to the Shareholders of the Company in due course. Shareholders of the Company are advised to read this announcement in conjunction with the FY2017 Annual Report.

BY ORDER OF THE BOARD

Raymond Lam Kuo Wei
Company Secretary

28 March 2018

*This announcement has been prepared by the Company and its contents have been reviewed by PrimePartners Corporate Finance Pte. Ltd. (the “**Sponsor**”), for compliance with the Catalist Rules. The Sponsor has not verified the contents of this announcement. This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg)